IDH1 and acute myeloid leukemia: The FDA accelerated approval for ivosidenib in 2018 was based on an open-label, single arm, multicenter phase 1 dose escalation and expansion study of ivosidenib in 179 patients with R/R AML with a confirmed IDH1 mutation [65].